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Magnetic resonance imaging (MRI) is a routine diagnostic tool in modern clinical medicine. 
MRI has many advantages as a diagnostic imaging modality. It is noninvasive, delivers no 
radiation, and has excellent (submillimeter) spatial resolution. Some Gadolinium(III) 
complexes are commonly used to enhance the contrast between adjacent tissues when the 
resolution/sensitivity of MRI is too low. Because free Gd3+ is very toxic in doses required for 
MRI, Gd(III) is chelated by poly(amino-carboxylate) such as diethylenetriamine pentaacetic 
acid (DTPA; scheme 1) or 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA; 
scheme 2)).  
 















                                                       Scheme 1     Scheme 2 
            
Although DTPA/Gd3+ and DOTA/Gd3+ are water soluble, they have a very short circulation 
lifetime in blood, a low molecular weight and a short rotational time that make the contrast 
poor. To enhance the contrast, the Gd3+/complex doses have to be increased.  
In order to increase the sensitivity of the technique, while not increasing the concentration of 
the contrast agent, we were investigating different strategies to improve (i) the circulation 
lifetime in blood, (ii) the relaxation rate of Gd(III) (and consequently, the contrasting 
efficiency) and (iii) the targeting of the contrast agent. This presentation aims at reporting 
how a multifunctional (co)polymer can be designed and exploited for improving the 
contrasting ability and bioavailability of gadolinium-based complexes.  
 
